Summary & Overview
HCPCS Level II J1573: Hepatitis B Immune Globulin Injection, IV 0.5 mL
HCPCS Level II code J1573 denotes a 0.5 mL intravenous dose of hepatitis B immune globulin (Hepagam B). This medication-specific code is used to bill for the injectable product administered to provide short-term passive immunity to hepatitis B after exposure or for certain prophylactic indications. Nationally, accurate coding for immune globulins matters for patient safety, inventory control, and consistent payment for high-cost biologic injectables.
Key payers included in the analysis are Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise overview of clinical context for use of hepatitis B immune globulin, common sites of service for intravenous administration, and payer coverage considerations. Where available, benchmarking content addresses unit-based billing, typical settings such as hospital infusion centers and clinics, and the role of this HCPCS Level II code in capturing the medication component of care.
This publication summarizes how J1573 is used in billing workflows and what elements are typically needed on the service line. Data not available in the input is flagged as such; the piece focuses on national-level interpretation of the code, clinical context, and payer coverage scope rather than state-specific policy or step-by-step clinical guidance.
Billing Code Overview
HCPCS Level II code J1573 represents an intravenous injection of hepatitis B immune globulin (Hepagam B) in a volume of 0.5 mL per unit. This code describes the medication administration itself rather than broader visit or facility services.
Service type: Intravenous medication administration / injectable immunoglobulin therapy
Typical site of service: Hospital inpatient or outpatient infusion center, emergency department, or clinic-based infusion suite
Data not available in the input.
Clinical & Coding Specifications
Clinical Context
A patient presents to an outpatient infusion center or hospital for passive immunization after a known or suspected exposure to hepatitis B virus (HBV). Typical scenarios include a neonate born to an HBsAg-positive mother, a healthcare worker with a recent needle-stick from an HBV-positive source, or an unvaccinated adult with recent household or sexual exposure to a person with acute hepatitis B. The product described by J1573 is hepatitis B immune globulin (Hepagam B) supplied as 0.5 ml for intravenous administration. Clinical workflow: initial evaluation and exposure risk assessment; verification of maternal or source HBV status and patient's prior vaccination/serology (e.g., HBsAb, HBsAg); informed consent and documentation of indication; preparation of IV access; administration of the immune globulin dose per weight-based or manufacturer dosing guidance; observation for immediate adverse reactions (30–60 minutes); documentation of lot number and expiration for cold-chain tracking; scheduling of hepatitis B vaccination series if indicated (e.g., at 0, 1–2, and 6 months for postexposure prophylaxis when recommended). Typical sites of service are an outpatient infusion center, emergency department, labor and delivery unit (for neonatal prophylaxis), or inpatient hospital setting for occupational exposures requiring urgent treatment.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
00 |